GlassScriptPhysician profile
Joanna Hoffman
NPI 1043754492
$4,490.08
in general payments reported to CMS, 2019-2025
26 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $836 · 2022: $470 · 2023: $969 · 2024: $999 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.96 |
| Education | $173.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $669.91 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $422.87 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $386.51 | 2022-2025 | Sotyktu |
| Abbvie INC. | $382.35 | 2022-2025 | |
| Janssen Biotech, INC. | $361.49 | 2021-2025 | Tremfya |
| Genzyme Corporation | $256.08 | 2021-2025 | |
| Ucb, INC. | $254.52 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $216.08 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $205.79 | 2021-2025 | |
| Leo Pharma INC. | $199.45 | 2021-2025 | Anzupgo, Adbry |
| Amgen INC. | $182.80 | 2021-2025 | Otezla, Otezla |
| Biofrontera INC. | $143.95 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $118.69 | 2021 | |
| Arcutis Biotherapeutics, INC. | $117.73 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $114.22 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $107.78 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $74.12 | 2021 | |
| Incyte Corporation | $69.21 | 2021-2025 | Opzelura, Opzelura |
| Botanix Sb INC | $60.69 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $39.78 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.11 | 2024 | Spevigo |
| Genentech USA, INC. | $22.05 | 2023 | Erivedge |
| Galderma Laboratories, L.P. | $16.77 | 2023 | Epsolay, Aklief, Oracea |
| Journey Medical Corporation | $14.72 | 2023 | |
| Verrica Pharmaceuticals INC. | $13.80 | 2024 | Ycanth |
| Organon LLC | $10.61 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.